Cefdinir

Selected mild/moderate indications include community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, streptococcal pharyngitis/tonsillitis and uncomplicated skin/skin-structure infections. Relevant organisms include susceptible H. influenzae/H. parainfluenzae, M. catarrhalis, penicillin-susceptible S. pneumoniae, S. pyogenes and methicillin-susceptible S. aureus according to the indication. Do not generalize each organism to every infection.

Pediatric uses from age 6 months include acute bacterial otitis media, acute maxillary sinusitis, S. pyogenes pharyngitis/tonsillitis and uncomplicated susceptible skin infections. Pediatric sinusitis approval is supported by adult evidence and pediatric PK; neonatal/younger-infant safety/effectiveness are not established. Cefdinir eradicates pharyngeal S. pyogenes, but prevention of rheumatic fever has not been studied.

Use for proven or strongly suspected susceptible bacterial infection and reassess available cultures/local resistance. It does not treat viral colds. Most Pseudomonas, Enterococcus, Enterobacter, MRSA and penicillin-resistant streptococcal strains are not covered. In-vitro activity against some urinary organisms does not establish a UTI approval, and human CSF penetration is unstudied; no UTI or meningitis regimen is supplied.

Usual total is 600 mg/day for adults/adolescents age 13 and older with normal renal function. The schedules below are from the coherent current comparator; the selected Lupin adult table shifts some infection names onto alternative-dose rows, while its prose explicitly requires twice-daily dosing for pneumonia/skin infection. Both sources are retained rather than propagate a once-daily skin regimen. Doses may be taken without regard to meals.

For ages 6 months through 12 years with normal renal function, usual total is 14 mg/kg/day, maximum 600 mg/day. Twice-daily means 7 mg/kg PERDOSE every 12 hours; once-daily means 14 mg/kg PERDOSE every 24 hours. Children ≥ 43 kg receive the 600 mg/day ceiling. Select frequency/duration by indication, not a universal interchangeable course.

At adult CrCl < 30 mL/min, dose 300 mg once daily. At pediatric estimated clearance < 30 mL/min/1.73 m², dose 7 mg/kg once daily, maximum 300 mg. Chronic hemodialysis labeling starts 300 mg or 7 mg/kg every other day, gives 300 mg or 7 mg/kg at the end of each session, then resumes every-other-day dosing. Dialysis timing must be coordinated with the prescriber/pharmacist; do not add unscheduled doses to an unchanged routine regimen. The pediatric renal value is indexed, unlike the adult CrCl threshold.

125 mg/5 mL is 25 mg/mL; 250 mg/5 mL is 50 mg/mL. Calculate the prescribed mg first, then measure the correct mL with an oral syringe; stronger suspension requires half the volume for the same mg. For either selected concentration, pharmacy reconstitution uses 38 mL water for a 60 mL final bottle or 61 mL for 100 mL, added in two portions with shaking after each. Shake before every administration; never use a kitchen spoon or another manufacturer’s water instructions.

Known allergy to the cephalosporin antibiotic class is a formal contraindication. Penicillin allergy is addressed as a cross-hypersensitivity precaution in these labels, requiring clinical evaluation rather than assuming all reported allergies are equivalent.

The selected current cefdinir labels do not contain a boxed warning. The prominent capitalized allergy warning and C. difficile warning remain important precautions even without a formal box.

Common adult effects include diarrhea, nausea, headache, abdominal symptoms and vaginal candidiasis. Children commonly experience diarrhea, rash and vomiting; diarrhea/diaper rash are more frequent in younger children. Postmarketing reports include severe allergic/skin reactions, blood-cell disorders, hepatic injury and renal failure; these reports do not define a reliable incidence or prove causality for every listed event.

Give cefdinir at least 2 hours before or after magnesium/aluminum antacids or iron supplements, including iron-containing multivitamins. These combinations reduce absorption. Iron-fortified infant formula does not significantly alter exposure in the reviewed suspension evidence and can be given with cefdinir; that exception does not apply to iron supplements or all highly fortified foods.

Probenecid inhibits renal cefdinir excretion and increases/prolongs exposure. Review treatment necessity, organ function and adverse effects rather than invent a fixed cefdinir reduction for that combination. The label’s possible postmarketing diclofenac interaction is a report of uncertain relationship, not a quantified universal dose algorithm.

Cefdinir with iron can form a nonabsorbed complex producing reddish stools; this does not rule out true bleeding or antibiotic-associated colitis. Some urine ketone/glucose methods can be falsely positive, while glucose-oxidase methods are preferred for urine glucose in the label. Cephalosporins can occasionally produce a positive direct Coombs test; inform the testing team.

The pediatric suspension regimen is for 6 months through 12 years; younger infants/neonates lack established safety/effectiveness. The adult/adolescent schedule starts at 13 years in the coherent comparator. Older patients need no age-only adjustment, but reduced renal clearance can require the 300 mg daily regimen. Consider frailty, adverse effects and the ability to measure suspension accurately.

Cefdinir exposure and half-life increase as renal function declines; reduce at the specified threshold and reassess transient/unstable renal dysfunction. Hemodialysis removes substantial drug and has a separate schedule. Hepatic studies were not performed because the drug is minimally metabolized and chiefly renally cleared; the label does not expect a hepatic-only adjustment, which is not evidence that severe combined organ disease needs no assessment.

Adequate controlled pregnancy studies are lacking; use when clearly needed after weighing infection/treatment risks. Animal findings do not establish absence of human risk, and the retained old pregnancy letter category is not presented as current risk certainty. Cefdinir was not detected in milk after a single 600 mg dose in the label; this limited result does not establish zero repeated-dose infant exposure or a universally safe lactation regimen. Labor/delivery use was not studied.

Selected Lupin suspension contains 2.86 g sucrose per 5 mL; account for this in diabetes and the prescribed volume. Excipients vary by manufacturer, so verify the actual product for allergies and dietary concerns.

Cefdinir is a cephalosporin with bactericidal activity from inhibition of cell-wall synthesis. It withstands some beta-lactamases, but resistance can occur through other beta-lactamases, altered penicillin-binding proteins and reduced permeability. MRSA and most Pseudomonas/Enterococcus are outside its reliable label spectrum.

Peak plasma levels occur about 2–4 hours after an oral dose. Capsule absolute bioavailability is about 21% at 300 mg and 16% at 600 mg; suspension averages 25%. Protein binding is 60–70%, appreciable metabolism does not occur, and normal-function elimination half-life averages 1.7 hours. Parent drug is predominantly renally cleared; the short usual half-life is not a reason to override validated infection-specific schedules.

A high-fat meal reduces exposure but the labels permit dosing without regard to meals based on clinical data. Selected 125/250 mg per 5 mL suspensions were bioequivalent under studied fasting conditions; suspension exposure relative to capsules is not identical in every PK measure. Hemodialysis removed about 63% in a 4-hour study, reinforcing the need for a specific dialysis plan rather than casual formulation/interval substitution.

Before treatment, assess allergy history, infection severity, culture/susceptibility information when available, renal function and interacting cation products. Follow response, diarrhea, rash and superinfection; repeat renal assessment when kidney function may change. The selected labels do not mandate one universal routine lab panel for every short uncomplicated course.

Take exactly as prescribed, including frequency and duration; do not share leftovers or use for viral colds. Discuss cation spacing and possible iron-related red stool. Seek prompt care for watery/bloody diarrhea even after completion, and immediate care for breathing difficulty, swelling or serious skin reactions. Do not self-assume red stool is harmless when accompanied by illness or bleeding concern.

Check both strength and prescribed mL, shake well, and use a calibrated oral syringe. Keep the reconstitution date/discard date visible; selected suspension expires 10 days after mixing. If doses are missed, the bottle is insufficient or symptoms worsen/fail to improve, contact the prescribing team for an individualized plan rather than doubling or extending treatment independently.

Lupin 300 mg capsule has a blue cap marked LUPIN and purple body marked CEFDINIR; 60 capsules are NDC 68180-711-60. Selected Lupin 250 mg/5 mL suspension 100 mL bottle is NDC 68180-723-05 and is strawberry-flavored/off-white to cream after mixing. Verify manufacturer and actual package; appearance alone is insufficient.

Selected capsules contain 300 mg cefdinir; selected powder yields 125 mg/5 mL or 250 mg/5 mL oral suspension in 60 or 100 mL final bottles. It is a single-ingredient oral antibacterial, not an IV product. Capsule adult and liquid pediatric labels provide complementary instructions; do not infer an injectable dose.

Store selected capsules and dry/reconstituted suspension at 20–25°C. Keep suspension tightly closed, shake before use, and discard unused liquid 10 days after preparation. Inspect the actual dispensed product’s instructions for handling; do not apply a different manufacturer’s refrigeration or reconstitution rule.